



US008748481B2

(12) **United States Patent**
Ueno(10) **Patent No.:** **US 8,748,481 B2**
(45) **Date of Patent:** **Jun. 10, 2014**(54) **METHOD FOR TREATING
GASTROINTESTINAL DISORDER**(75) Inventor: **Ryuji Ueno**, Montgomery, MD (US)(73) Assignee: **Sucampo AG**, Zug (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **11/216,012**(22) Filed: **Sep. 1, 2005**(65) **Prior Publication Data**

US 2006/0063830 A1 Mar. 23, 2006

Related U.S. Application Data

(60) Provisional application No. 60/606,521, filed on Sep. 2, 2004, provisional application No. 60/666,317, filed on Mar. 30, 2005, provisional application No. 60/666,593, filed on Mar. 31, 2005.

(51) **Int. Cl.**
A61K 31/352 (2006.01)(52) **U.S. Cl.**
USPC **514/456**; 514/892(58) **Field of Classification Search**
None
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

5,166,174	A	11/1992	Ueno et al.
5,225,439	A	7/1993	Ueno et al.
5,284,858	A	2/1994	Ueno et al.
5,317,032	A	5/1994	Ueno et al.
5,380,709	A	1/1995	Ueno et al.
5,428,062	A	6/1995	Ueno et al.
5,886,034	A	3/1999	Ueno et al.
6,265,440	B1	7/2001	Ueno et al.
6,414,016	B1	7/2002	Ueno
6,583,174	B1	6/2003	Ueno et al.
6,610,732	B2	8/2003	Ueno
6,956,056	B2	10/2005	Ueno
6,982,283	B2	1/2006	Ueno
7,064,148	B2	6/2006	Ueno et al.
2003/0119898	A1	6/2003	Ueno et al.
2003/0130352	A1	7/2003	Ueno et al.
2003/0166632	A1	9/2003	Ueno
2004/0138308	A1	7/2004	Ueno et al.
2004/0235885	A1	11/2004	Ueno et al.
2005/0222195	A1	10/2005	Ueno
2005/0261375	A1	11/2005	Ueno
2006/0122411	A1	6/2006	Ueno et al.
2006/0240106	A1	10/2006	Ueno

FOREIGN PATENT DOCUMENTS

WO WO 2004/060377 A1 7/2004

OTHER PUBLICATIONSThe Merck Index, 17th edition (1999) pp. 221-223.*
Drossman et al., American Journal of Gastroenterology, 95(4) (2000), pp. 999-1007.*[http://www.askapatient.com/viewrating.asp?drug=20698
&name=MIRALAX.*](http://www.askapatient.com/viewrating.asp?drug=20698&name=MIRALAX.*)

Kinservik et al., "The efficacy and safety of polyethylene glycol 3350 in the treatment of constipation in children", Pediatric Nursing, May-Jun. 2004, vol. 30(3), pp. 232-237.*

"About Cystic Fibrosis", Cystic Fibrosis Foundation, downloaded on May 21, 2009 from "http://www.cff.org/AboutCF/", p. 1 of 1.*

Eggermont et al., "Small-intestinal abnormalities in cystic fibrosis patients", 1991, European Journal of Pediatrics, vol. 150, pp. 824-828.*

Chung et al., Canadian Family Physician, May 2009, vol. 55, pp. 481-482.*

[http://www.askapatient.com/viewrating.asp?drug=20698
&name=MIRALAX;](http://www.askapatient.com/viewrating.asp?drug=20698&name=MIRALAX;) downloaded on Mar. 11, 2008.*

L. A. Sorbera et al., "Lubiprostone. Treatment of Constipation, Treatment of Irritable Bowel Syndrome, Treatment of Postoperative Ileus, CIC-2 Channel Activator", Drugs of the Future, Apr. 2004, vol. 29, No. 4, pp. 336-341, XP008055565.

N J Talley, "Definitions, Epidemiology, and Impact of Chronic Constipation", Reviews in Gastroenterological Disorders, vol. 4, No. Suppl. 2, 2004, pp. S3-S10, XP0080055601.

Irvine E J et al.; Health-Related Quality of Life in Functional GI Disorders: Focus on Constipation and Resource Utilization; American Journal of Gastroenterology, vol. 97, No. 8, Aug. 2002, pp. 1986-1993.

Joseph H. Sellin, Intestinal Electrolyte Absorption and Secretion; Pathophysiology, Diagnosis, and Management, pp. 1451-1471 (WB Saunders Company, 1998), Chapter 86.

André Robert, Prostaglandins and the Gastrointestinal Tract, Chapter 57, Physiology of the Gastrointestinal Tract, edited by Leonard R. Johnson, Raven Press, New York, 1981, pp. 1407-1434.

D.S. Rampton, Prostanoids and intestinal physiology, Biology and Chemistry of Prostaglandins and Related Eicosanoids, pp. 323-344 (Churchill Livingstone, 1988).

C. J. Hawkey and D.S. Rampton; Prostaglandins and the Gastrointestinal Mucosa: Are They Important in Its Function, Disease, or Treatment?, Gastroenterology 1985; 89: 1162-88.

Charles E. Eberhart and Raymond N. Dubois; Eicosanoids and the Gastrointestinal Tract, Gastroenterology 1995; 109:285-301.

André Robert, Antisecretory, Antiulcer, Cytoprotective and Diarrheogenic Properties of Prostaglandins; Advances in Prostaglandin and Thromboxane Research, vol. 2, 1976, pp. 507-520.

(Continued)

Primary Examiner — Savitha Rao*Assistant Examiner* — Gregg Polansky(74) *Attorney, Agent, or Firm* — Sughrue Mion, PLLC(57) **ABSTRACT**

The present invention relates to a method for the long term treatment of gastrointestinal disorders in a human subject, which comprises administering an effective amount of a halogenated prostaglandin compound and/or its tautomer to the subject. The method induces substantially no electrolyte shifting during the term of the treatment. The compound used in the present invention can improve quality of life in the human subjects with gastrointestinal disorders, are similarly effective in treating male and female subjects, and also effective in a human subject aged even 65 years and older.